Abstract
Abstract During the mid-1980s, gene therapy was investigated as a possible therapeutic regimen for diseases caused by single gene defects, for example haemophilia, Duchenne’s muscular dystrophy, and sickle cell anaemia. In the late 1980s and early 1990s, the concept of gene therapy expanded into a number of acquired diseases. Gene therapy can be targeted to somatic (body) or germ (egg and sperm) cells. In somatic gene therapy the recipient genome is changed, but the change is not passed along to the next generation. This form of gene therapy is contrasted with germline gene therapy where the goal is to pass change on to the offspring [1].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
